Shuangyou Liu

5PUBLICATIONS
0CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Apr 20, 2025
CD58 could be a leukemic marker in patients with relapsed/refractory B-cell acute lymphoblastic leukemia after multiline therapies.

Xinjian Yu, Pan Li, Heyuan Feng

|Aug 22, 2022
CAR-T therapy as a consolidation in remission B-ALL patients with poor prognosis.

Zhichao Yin, Yuehui Lin, Dan Liu

|Apr 12, 2022
Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy.

Lihong An, Yuehui Lin, Biping Deng

|Feb 18, 2022
Quick identification of target antigens by tissue flow cytometry for CAR-T therapy in B-cell malignancies.

Xinjian Yu, Pan Li, Anne Aofan Wang

|Mar 16, 2021
Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.

Shuangyou Liu, Biping Deng, Zhichao Yin

Pageof 1

Frequent Collaborators